Browsing Tag
AnaptysBio
6 posts
Why AnaptysBio’s new CFO hire may matter more than a routine biotech appointment
AnaptysBio is no longer a classic biotech pipeline bet. Christopher Murphy’s CFO appointment tests whether ANAB can execute as a royalty vehicle.
How AnaptysBio’s 2026 spin-off plan could reshape its pipeline, royalty flows, and stock outlook
Discover how AnaptysBio (NASDAQ: ANAB) plans to split into two focused companies to unlock hidden value and reshape its investment story.
AnaptysBio shares soar 37% after rheumatoid arthritis candidate rosnilimab delivers promising Phase 2b trial results
AnaptysBio, Inc. experienced a significant boost in its market performance as shares surged 37% in premarket trading following…
AnaptysBio abandons eczema drug after trial failures; shares nosedive
Biotechnology company AnaptysBio, Inc., specializing in innovative autoimmune disease therapies, announced it will halt development of its atopic…
GSK secures expanded approval for Jemperli from FDA: A major advancement in endometrial cancer treatment
In a landmark decision, the US Food and Drug Administration (FDA) has extended its approval of Jemperli (dostarlimab)…
GSK secures full Jemperli FDA approval for endometrial cancer treatment
Biopharma company GSK has secured the full approval of the US Food and Drug Administration (FDA) for its…